Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

We recently published a list of Top 10 Best Dividend Stocks on Robinhood. In this article, we are going to take a look at ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Merck did not comment on Kennedy's role ... at The Wall Street Journal covering bankruptcy, private equity, mergers and acquisitions and the automotive industry. Elon Musk told investors in ...

Additionally, the company has been using mergers and acquisitions (M&A ... (see more details here). Merck & Co., Inc. (NYSE:MRK) is a New Jersey-based pharmaceutical company that offers innovative ...

Merck (NSE:PROR) & Co., Inc. (NYSE ... network via organic expansions and acquisitions and has been on a mergers and acquisitions (M&A) binge in recent years. In 2023, it bought Magellan Midstream ...

While Merck has traditionally relied more on its internal R&D capabilities than mergers and acquisitions to grow its business, new chief executive Robert Davis said earlier this year that approach ...

Monroe Capital LLC ("Monroe") announced it acted as sole lead arranger and administrative agent on the funding of a senior credit facility to support Aligned Exteriors Group's ("AEG") acquisition of ...

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.